Developing 3D organoid models to better understand pancreatic cancer treatment resistence

Nelson Dusetti shared a post by Institute Paoli-Calmettes, on Linkedin:

”We are excited about the impactful discoveries this collaboration will bring in the fight against pancreatic cancer!”

Quoting Institute Paoli-Calmettes‘s post:

” We are excited to announce a new collaboration between Servier Paris-Saclay Research and Development Institute, the Institut Paoli-Calmettes, and the Translational Research and Therapeutic Targets in Pancreatic Cancer team at CRCM – Centre de Recherche en Cancérologie de Marseille.

This partnership will focus on developing advanced 3D organoid models to better understand pancreatic cancer treatment resistence and improve drug screening.

Our goal is to advance personalized treatment approaches and overcome key challenges in chemoresistance. Public-private partnerships are invaluable in fostering innovation in cancer treatment and align perfectly with our team’s commitment to translational research.

We are excited about the impactful discoveries this collaboration will bring in the fight against pancreatic cancer!”

Source: Nelson Dusetti/Linkedin and Institut Paoli-Calmettes/Linkedin

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.